Don't close this page .. Test is protected .. Answers cannot be changed .. We try now to connect to save and correct your answers.
Connection trial number:
If this message persists for long, please check your internet connection.
This test is monitored
Switching to another webpage or any other program is considered a cheating behavior and your test may be automatically terminated.
Okay
Important Notice
If you moved to the next question, you will not be able to come back to this question again.
Cancel
Move to next question
Final exam لمادة موضوعات مختارة في علم الادوية
Student data
×
Student data
Student name: ***
Student number: ***
Class or section: ***
Test instructions
×
Test instructions
عدد الاسءلة هي 63 سؤال
Page direction
×
Change page direction
Right to left
Left to right
Q1
Score: 0.5
A- strength of hypothesis
B- Availibility of target
C- market prediction
D- Toxicology
Q2
Score: 0.5
A- spontaneous
B- route of exposure
C- species
D- sex of test animal formulation
Q3
Score: 0.5
Q4
Score: 0.5
A- check chemical stability
B- determine major metabolite
C- optimize and scale up synthesis and purification
D- produce GMP batches are required for biological and clinical test
Q5
Score: 0.5
A- usually placebo controlled
B- phase IIa is exploratory and phase IIb is confirmatory
C- the opproxinate number of healthy subject is 50- 500
D- gives confirmation of clinical dose and regimen for efficacy
Q6
Score: 0.5
A- chemical development
B- safety assessment
C- drug metabolism
D- all the above
Q7
Score: 0.5
صح
خطأ
Q8
Score: 0.5
A- Aspirin
B- sulfonamide
C- chloramphenicol
D- Tetracycline
Q9
Score: 0.5
A- digoxin
B- NSAIDS
C- Atropine- like drugs
Q10
Score: 0.5
Q11
Score: 0.5
صح
خطأ
Q12
Score: 0.5
A- Health
B- disease
C- organization
D- non the above
Q13
Score: 0.5
Q14
Score: 0.5
A- gene
B- protein
C- cell
D- tissue
Q15
Score: 0.5
A- phase -1
B- phase- 2
Q16
Score: 0.5
A- digoxin
B- TCAS
C- Atropine like drugs
Q17
Score: 0.5
A- sulfonamide
B- Aspirin
C- Mepiridine
D- Benzodiazepine
Q18
Score: 0.5
صح
خطأ
Q19
Score: 0.5
A- Antibodies
B- vaccines
C- enzyme
D- DNA product
Q20
Score: 0.5
A- Clark's Rule
B- Youngs Rule
C- creatinine clearance
D- non the above
Q21
Score: 0.5
Q22
Score: 0.5
A- drug action
B- cell
B- tissue
C- system
Q23
Score: 0.5
A- treatment of pre- existing chronic disorder
B- always use drugs which have been widely used
C- over the counter
D- drugs for medical condition prior to confirmation of pregnancy
Q24
Score: 0.5
A- Arthritis
B-metabolism
C- peptic ulcer
D- stroke
Q25
Score: 0.5
A- producing hypotension
B- producing hypoglycemia
C- producing hypertension
D- producing hyperglycemia
Q26
Score: 0.5
Q27
Score: 0.5
A- animal
B- human
C- in vivo
Q28
Score: 0.5
A- Elderly people
B- Infant
C- they are the major consumer of drug
D- include polypharmacy
Q29
Score: 0.5
Q30
Score: 0.5
صح
خطأ
Q31
Score: 0.5
صح
خطأ
Q32
Score: 0.5
صح
خطأ
Q33
Score: 0.5
A- FDA
B- NMR
C- IND
Q34
Score: 0.5
Q35
Score: 0.5
Q36
Score: 0.5
صح
خطأ
Q37
Score: 0.5
A- structural
B- spontaneous
C- antidotal
D- route of exposure
Q38
Score: 0.5
صح
خطأ
Q39
Score: 0.5
صح
خطأ
Q40
Score: 0.5
A- lethal dose to assayed in the same population
B- dose required for sub- lethal toxicity
C- all the above
Q41
Score: 0.5
صح
خطأ
Q42
Score: 0.5
A- nasal hypoplasia
B- bone stippling on X- Ray
C- depressed bridge of nose
D- all the above
E- non the above
Q43
Score: 0.5
A- Easily
B- with difficult
C- poorly
D- non of the above
Q44
Score: 0.5
صح
خطأ
Q45
Score: 0.5
A- absorption
B- medication compliance
C- reduction in GI motility
D- Elimination
E- A+ D
F- all the above
Q46
Score: 0.5
صح
خطأ
Q47
Score: 0.5
صح
خطأ
Q48
Score: 0.5
A- pharmaceutic interaction
B- pharmacodynamic interaction
C- pharmacokinetic interaction
Q49
Score: 0.5
A- albumin
B- alpha-1 acid glycoproteins
C- T cell
Q50
Score: 0.5
A- dose
B- Age
C- systemic toxicity
D- Route
Q51
Score: 0.5
A- 5- 10 years
B- 1 month
C- 15- 25 years
D- 9 month to 3 years
Q52
Score: 0.5
صح
خطأ
Q53
Score: 0.5
A- vaccination
B- blood transfusion
C- transplantation
D- drug therapy
Q54
Score: 0.5
A- poly pharmacy
B- multiple disease state
C- increase severity of illness
D- B+ C
E- all the above
Q55
Score: 0.5
Q56
Score: 0.5
A- result in polar
B- water soluble
C- oxidase
D- conjugation
Q57
Score: 0.5
A- urinary retention
B- hyperglycemia
C- heart block
D- GI hemorrhage
Q58
Score: 0.5
A- pregnancy
B- cough
C- diarrhea
D- heart
Q59
Score: 0.5
A- In vivo
B- in human
C- in animal
D- in vitro
Q60
Score: 0.5
A- pharmacodynamic drug- drug interaction
B- pharmacokinetic drug- drug interaction
C- pharmaceutic interaction
Q61
Score: 0.5
صح
خطأ
Q62
Score: 0.5
Q63
Score: 0.5
صح
خطأ
Q64
Score: 0.5
A- Effect
B- Efficacy
C- Effectiveness
D- BENEFIT
Q65
Score: 0.5
A- category A
B- category B
C- category c
D- category D
E- category x
Q66
Score: 0.5
A- factor including the vascular perfusion
B- By 6 weeks of age
C- such as penicillin
D- are reduced by 50% in premature
Q67
Score: 0.5
صح
خطأ
Q68
Score: 0.5
A- phase I
B- phase II
C- phaseI and II and III and IV
D- phase III
Q69
Score: 0.5
Q70
Score: 0.5
A- mental retardation
B- Mutagenesis
C- is seen in up to 25% of the fetuses with first - trimester exposure to coumarins
D- carcinogenesis
Q71
Score: 0.5
صح
خطأ
Q72
Score: 0.5
A- fetal period
B- organogenesis
C- Blastogenesis
D- non the above
Q73
Score: 0.5
صح
خطأ
Q74
Score: 0.5
A- mental retardation
B- Hyperactivity
C- all the above
D- non of the above
Q75
Score: 0.5
A- conducting a clinical trial
B- Analyzing the outcome of a clinical trial
C- Givrine permission so clinical trial
D- non the above
Q76
Score: 0.5
A- chemical modification of known molecule
B- biotechnology and cloning
C- random screening for biological activity of large numbers of natural
D- all the above
Q77
Score: 0.5
A- drugs
B- food additives
C- cosmetic
D- pesticide
E- all of the above
Q78
Score: 0.5
A- transplant surgery
B- Apligraf
C- B cell
D- influenza
Q79
Score: 0.5
A- pharmacodynamic
B- direct toxicity
C- genotoxicity
D- all the above
Q80
Score: 0.5
صح
خطأ
Questions you haven't answered yet:
Are you sure you want to end this test and send your answers?
All copy rights reserved
©
arab-exams.com
2014-2023
Dismiss this alert